Spero director granted RSUs and stock options
Spero Therapeutics director Milind Deshpande received new equity awards as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Spero Therapeutics director Milind Deshpande received new equity awards as part of his compensation. He was granted 10,000 restricted stock units, each representing one share of common stock upon vesting, and a stock option for 20,000 shares at an exercise price of $2.15 per share.
The RSUs vest on June 23, 2027, contingent on his continued service. The option also vests and becomes fully exercisable on June 23, 2027 under the same service condition. Following the grant, he directly holds 101,454 shares of common stock.
Insider Trade Summary
Grant/Award: 30,000 shares
Grant/Award
2 txns
Insider
Deshpande Milind
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 20,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 10,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 20,000 contracts (Direct);
Common Stock — 101,454 shares (Direct)
Footnotes (2)
- F1. Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
- F2. The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Key Figures
RSU grant: 10,000 shares
Stock option grant: 20,000 shares
Option exercise price: $2.15/share
+4 more
7 metrics
RSU grant
10,000 shares
Restricted stock units granted to director
Stock option grant
20,000 shares
Option on common stock granted to director
Option exercise price
$2.15/share
Exercise price for 20,000-share option
Shares held after grant
101,454 shares
Common stock directly owned after transaction
RSU vesting date
June 23, 2027
RSUs vest if service continues through this date
Option vesting date
June 23, 2027
Option becomes fully exercisable on this date
Option expiration
June 23, 2036
Expiration date of the stock option
Key Terms
restricted stock units, Stock Option (right to buy), exercise price, vesting, +1 more
5 terms
restricted stock units financial
"Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (right to buy) financial
"Stock Option (right to buy) with underlying security title Common Stock and 20,000.0000 underlying shares."
exercise price financial
"conversion_or_exercise_price: "2.1500" for the stock option grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 4 regulatory
"INSIDER FILING DATA (Form 4) reporting transactions in Spero Therapeutics, Inc."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Spero Therapeutics (SPRO) report for Milind Deshpande?
Spero Therapeutics reported that director Milind Deshpande received equity awards consisting of 10,000 restricted stock units and a stock option on 20,000 shares of common stock as part of his compensation package.
What are the vesting terms for the new RSUs reported by Spero Therapeutics (SPRO)?
The 10,000 restricted stock units granted to Milind Deshpande vest on June 23, 2027. Each RSU converts into one share of common stock if he continues to serve through that vesting date, aligning incentives with long-term company performance.
What are the key details of the stock option granted to Milind Deshpande at Spero Therapeutics?
Milind Deshpande received a stock option for 20,000 shares of common stock with an exercise price of $2.15 per share. The option vests and becomes fully exercisable on June 23, 2027, subject to his continued service as a director.
Is the Form 4 for Spero Therapeutics (SPRO) an open-market purchase or a compensation grant?
The Form 4 shows a compensation grant, not an open-market trade. Both the 10,000 RSUs and the 20,000-share stock option are reported under code A, indicating awards or other acquisitions rather than market purchases.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates